FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer – The ASCO Post

By The ASCO Post StaffPosted: 12/23/2019 7:33:00 AM Last Updated: 12/23/2019 12:47:12 PM On December 20, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive breast cancer…

Read the full article here

Related Articles